July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
ENDOTHELIAL VASCULAR GROWTH FACTOR POLYMORPHISM -634 C/G ASSOCIATION WITH THE BEVACIZUMAB INTRAVITREAL THERAPY RESPONSE IN LATIN POPULATION WITH DIABETIC MACULAR EDEMA.
Author Affiliations & Notes
  • Geovanni Jassiel Rios
    Retina , Hospital de La Luz , MExico, Mexico, Mexico
  • Ramirez Abel
    Retina , Hospital de La Luz , MExico, Mexico, Mexico
  • Footnotes
    Commercial Relationships   Geovanni Rios, None; Ramirez Abel, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3599. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Geovanni Jassiel Rios, Ramirez Abel; ENDOTHELIAL VASCULAR GROWTH FACTOR POLYMORPHISM -634 C/G ASSOCIATION WITH THE BEVACIZUMAB INTRAVITREAL THERAPY RESPONSE IN LATIN POPULATION WITH DIABETIC MACULAR EDEMA.
      . Invest. Ophthalmol. Vis. Sci. 2018;59(9):3599. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The aim of the study is to know the prevalence of VEGF polymorphisms (-634 C/G) and its relationship with therapeutic success in patients with diabetic macular edema.

Methods : We conducted a prospective, longitudinal study. , We analyzed 81 samples of patients treated with intravitreous bevacizumab, peripheral blood DNA extraction was performed with the labeling of the VEGF gene promoter region -634, they were cataloged in responders and non-responders depending on Central macular thickness measured with OCT (Heidelberg) baseline, first and third month post injection, and analyzed for the genotype frequency.

Results : Analyzing the genotype frequency, we can observe an adequate response rate of 33% in GG (-634), GC 57% and CC only 10%. The presence of CC genotype presents a relative risk of 2.35 times less response to antiangiogenic treatment compared to GG genotype.

Conclusions : In our study, the presence of VEGF-634 C / C polymorphism is more frequent in Latino patients with poor response to treatment of diabetic macular edema with intravitreal bevacizumab

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×